| Literature DB >> 33411320 |
Mingming Zhao1, Zheyu Wang2,3, Ming Yang1, Yan Ding3,4, Ming Zhao1, Haijing Wu5, Yan Zhang6,7,8,9, Qianjin Lu10,11.
Abstract
G protein-coupled receptors (GPCRs) constitute the largest family of plasma membrane receptors in nature and mediate the effects of a variety of extracellular signals, such as hormone, neurotransmitter, odor, and light signals. Due to their involvement in a broad range of physiological and pathological processes and their accessibility, GPCRs are widely used as pharmacological targets of treatment. Orphan G protein-coupled receptors (oGPCRs) are GPCRs for which no natural ligands have been found, and they not only play important roles in various physiological functions, such as sensory perception, reproduction, development, growth, metabolism, and responsiveness, but are also closely related to many major diseases, such as central nervous system (CNS) diseases, metabolic diseases, and cancer. Recently, many studies have reported that oGPCRs play increasingly important roles as key factors in the occurrence and progression of autoimmune diseases. Therefore, oGPCRs are likely to become potential therapeutic targets and may provide a breakthrough in the study of autoimmune diseases. In this article, we focus on reviewing the recent research progress and clinical treatment effects of oGPCRs in three common autoimmune diseases: multiple sclerosis (MS), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE), shedding light on novel strategies for treatments.Entities:
Keywords: G protein-coupled receptors; Multiple sclerosis; Orphan G protein-coupled receptors; Rheumatoid arthritis; Systemic lupus erythematosus
Year: 2021 PMID: 33411320 DOI: 10.1007/s12016-020-08829-y
Source DB: PubMed Journal: Clin Rev Allergy Immunol ISSN: 1080-0549 Impact factor: 8.667